Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Alejandro Rodriguez-Garcia, Alejandro Babayan-Sosa, Arturo Ramirez-Miranda, Concepcion Santa Cruz-Valdes, Everardo Hernandez-Quintela, Julio C Hernandez-Camarena, Nallely Ramos-Betancourt, Regina Velasco-Ramos & Raul E Ruiz-Lozano. (2022) A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel. Clinical Ophthalmology 16, pages 1331-1355.
Read now
Read now
Laura M Periman, Francis S Mah & Paul M Karpecki. (2020) A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments. Clinical Ophthalmology 14, pages 4187-4200.
Read now
Read now
Vinod Burade, Rishit Zalawadia, Alpesh Patel & Abayomi Ogundele. (2020) Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease. Clinical Ophthalmology 14, pages 2747-2755.
Read now
Read now
Gary W Jerkins, Guruprasad R Pattar & Shane R Kannarr. (2020) A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca. Clinical Ophthalmology 14, pages 481-489.
Read now
Read now
Tatiana Deveney & Penny A Asbell. (2018) Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. Clinical Ophthalmology 12, pages 569-576.
Read now
Read now
Michelle K Rhee & Francis S Mah. (2017) Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature. Clinical Ophthalmology 11, pages 1157-1166.
Read now
Read now
Nariman Nassiri, Yasaira Rodriguez Torres, Zachary Meyer, Michael A. Beyer, Gautham Vellaichamy, Amar S. Dhaliwal, Neil Chungfat & Frank S. Hwang. (2017) Current and emerging therapy of dry eye disease. Part A: pharmacological modalities. Expert Review of Ophthalmology 12:4, pages 269-297.
Read now
Read now
Articles from other publishers (20)
Elyana Vittoria Tessa Locatelli, Kelly Ann Acuna, Jason Betz, Arianna Alicia Tovar & Anat Galor. (2023) Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease. Cornea Publish Ahead of Print.
Crossref
Crossref
Run Bai, Li-ping Liu, Zhen Chen & Qiong Ma. (2022) Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease. Journal of Ophthalmology 2022, pages 1-6.
Crossref
Crossref
Bridgitte Shen Lee, Melissa Toyos, Paul Karpecki, Jessica Schiffbauer & John Sheppard. (2022) Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials. Ophthalmology and Therapy 11:4, pages 1333-1369.
Crossref
Crossref
Ji Eun Kim, Na Rae Kim, Hee Seung Chin, Kyoung Yul Seo, Tae-im Kim & Ji Won Jung. (2021) Factors associated with ocular surface epithelial damage in patients with primary Sjögren’s syndrome. BMC Ophthalmology 21:1.
Crossref
Crossref
Wen-yan Peng, Rong-xin Chen, Hong Dai, Lei Zhu, Ying Li, Zi-qing Gao, Xiao-yi Li & Shi-you Zhou. (2021) Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study. Clinical Therapeutics 43:3, pages 613-628.
Crossref
Crossref
Jeongah ShinChang Rae RhoJoon Young HyonTae-Young ChungKyung Chul YoonChoun-Ki Joo. (2021) A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics 37:1, pages 4-11.
Crossref
Crossref
Richard Lindstrom, Eric Donnenfeld, Edward Holland, Vicken KarageozianJohn ParkMelvin SaraybaLisa KarageozianJanine AubelHampar Karageozian. (2020) Safety and efficacy of ALG-1007 topical ophthalmic solution – A synthetic peptide that regulates inflammation, in patients with dry eye disease: An exploratory Phase I, open-label, single-center clinical study. American Journal of Ophthalmic Clinical Trials 3, pages 10.
Crossref
Crossref
Jarmo Laihia, Riikka Järvinen, Edward Wylęgała & Kai Kaarniranta. (2019) Disease aetiology‐based design of multifunctional microemulsion eye drops for moderate or severe dry eye: a randomized, quadruple‐masked and active‐controlled clinical trial. Acta Ophthalmologica 98:3, pages 244-254.
Crossref
Crossref
Preeya K. Gupta, Penny Asbell & John Sheppard. (2020) Current and Future Pharmacological Therapies for the Management of Dry Eye. Eye & Contact Lens: Science & Clinical Practice 46:2, pages S64-S69.
Crossref
Crossref
Robert Smyth-MedinaJosh JohnstonDouglas K. DevriesApril JasperShane R. KannarrBarry A. SchechterBridgitte Shen LeeGeorge VargheseAbayomi OgundeleCharles H. DarbyPaul KarpeckiJodi Luchs. (2019) Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials. Journal of Ocular Pharmacology and Therapeutics 35:7, pages 388-394.
Crossref
Crossref
David L. Wirta, Gail L. Torkildsen, Helen R. Moreira, John D. Lonsdale, Joseph B. Ciolino, Garrit Jentsch, Michael Beckert, George W. Ousler, Philipp Steven & Sonja Krösser. (2019) A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. Ophthalmology 126:6, pages 792-800.
Crossref
Crossref
Nora Aszodi, Stephan Thurau, Marlene Seegräber, Marjolein Bruin‐Weller & Andreas Wollenberg. (2019) Management der Dupilumab‐assoziierten Konjunktivitis beim atopischen Ekzem. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 17:5, pages 488-492.
Crossref
Crossref
Nora Aszodi, Stephan Thurau, Marlene Seegräber, Marjolein Bruin‐Weller & Andreas Wollenberg. (2019) Management of dupilumab‐associated conjunctivitis in atopic dermatitis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 17:5, pages 488-491.
Crossref
Crossref
Carolyn Begley, Barbara Caffery, Robin Chalmers, Ping Situ, Trefford Simpson & J. Daniel Nelson. (2019) Review and analysis of grading scales for ocular surface staining. The Ocular Surface 17:2, pages 208-220.
Crossref
Crossref
Eun Hae ShinDong Hui LimChan Min YangTae-Young Chung. (2019) Comparison of Efficacy and Sensation of Instillation between 0.05% Cyclosporine Nanoemulsion and Microemulsion Type. Journal of the Korean Ophthalmological Society 60:3, pages 239.
Crossref
Crossref
Karl Stonecipher, Gail Torkildsen, Eugene McLaurin, Linda Villanueva, George Ousler & David A Hollander. (2019) Efficacy and Safety of Topical Cyclosporine in Dry Eye Subjects Who Engage in Electronic Visual Tasking—The EMPOWER Study. US Ophthalmic Review 12:2, pages 88.
Crossref
Crossref
Lian Cui, Ying Li, Hyo Seok Lee, Jee Myung Yang, Won Choi & Kyung Chul Yoon. (2017) Effect of diquafosol tetrasodium 3% on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye. International Ophthalmology 38:5, pages 2021-2030.
Crossref
Crossref
Andrea Luaces-Rodríguez, Rosario Touriño-Peralba, Iria Alonso-Rodríguez, Xurxo García-Otero, Miguel González-Barcia, María Teresa Rodríguez-Ares, Laura Martínez-Pérez, Pablo Aguiar, Noemí Gómez-Lado, Jesús Silva-Rodríguez, Michel Herranz, Álvaro Ruibal-Morell, María Jesús Lamas, Francisco J. Otero-Espinar & Anxo Fernández-Ferreiro. (2018) Preclinical characterization and clinical evaluation of tacrolimus eye drops. European Journal of Pharmaceutical Sciences 120, pages 152-161.
Crossref
Crossref
Rosanna Dammacco. (2017) Systemic lupus erythematosus and ocular involvement: an overview. Clinical and Experimental Medicine 18:2, pages 135-149.
Crossref
Crossref
Andreina Tarff & Ashley Behrens. (2017) Ocular Emergencies. Medical Clinics of North America 101:3, pages 615-639.
Crossref
Crossref